Tagged with DIA

Denmark Henrik Schimmell outlines the critical importance of blood gas testing – a field in which Radiometer has long been a pioneer – and how the company’s portfolio of diagnostic tools has evolved over time. Schimmel also touches on what makes Radiometer a great place to work, how it interacts with…

Global On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from…

Turkey Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive collaboration agreement with Dutch biotech Sulfateq BV for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative…

Mexico Writing in the November issue of DIA Global Forum, Lawrence Liberti, Mario Alanis, Pravin Chopra, and Silvia Bendiner examine how the COVID-19 pandemic facilitated greater inter-stakeholder collaboration across the healthcare ecosystems in Cuba and Mexico, and how the learnings from this period can be leveraged for better patient outcomes moving…

Australia In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already making to the global innovative pharmaceutical industry and why his country remains a particularly attractive clinical trials hub.   “We…

Turkey Genz Biotechnology is a biotech startup working on novel diagnostic testing solutions. Its founder and CEO, Umut Ağyüz, explains the origins of the company, the big opportunities that have arisen due to the COVID-19 pandemic, and how their solutions are a great match for low-income and rural communities.   Things…

Denmark Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through the COVID-19 pandemic, the evolving access landscape for the company’s next-generation diabetes and obesity treatments, and why Denmark – despite…

Global With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why the peptide field is generating so much excitement, outline some of the most significant recent breakthroughs and big-ticket investments, and…

Turkey General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just one month after the World Health Organization made an official pandemic declaration. In addition, she categorizes the government’s response to…

Denmark Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the swift progress that the Danish biotech has made in his two and a half years as CEO. Dulac also highlights…

USA Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also explains how the work of his CAR-T team at the University of Washington School of Medicine could provide proof of…

Canada In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies like CADTH has evolved, the most significant challenges in their work, international collaboration, and RWE integration.   Health technology assessment…